Certara, Inc. (CERT)

16.30 -0.15 (-0.91%) At close: 04:00PM EDT

Certara, Inc.

100 Overlook Center
Suite 101
Princeton, NJ 08540
United States
609 716 7900
https://www.certara.com

Sector(s): Healthcare
Industry: Health Information Services
Full Time Employees: 1,338

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. William F. Feehery Ph.D.	CEO & Director	1.32M	N/A	1971
Mr. Leif E. Pedersen	President & Chief Commercial Officer	609.11k	N/A	1965
Mr. John E. Gallagher III	SVP, Principal Accounting Officer & Chief Financial Officer	1.07M	N/A	1973
Dr. Robert P. Aspbury Ph.D.	President of Certara Scientific Software	552.23k	N/A	1972
Dr. Patrick F. Smith Pharm.D.	President of Certara Drug Development Solutions	582.02k	N/A	1971
Mr. Max Kanevsky	Chief Technology Officer	N/A	N/A	N/A
Prof. Amin Rostami PharmD, Ph.D., FCP	Chief Scientific Officer	N/A	N/A	N/A
Mr. Richard M. Traynor	Senior VP, General Counsel & Secretary	N/A	N/A	1972
Mr. Ron DiSantis	Senior Vice President of Corporate Development	N/A	N/A	N/A
Ms. Sheila Rocchio MBA	Chief Marketing Officer	N/A	N/A	N/A

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Certara, Inc., together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics. The company provides Simcyp Simulator, a mechanistic biosimulation platform mechanistic biosimulation investigational new drug and translational stages; Simcyp Biopharmaceutics, used to identify and refine drug formulations; and Simcyp Secondary Intelligence which integrates toxicology with quantitative analysis of networks of molecular and functional biological changes to identify drug toxicity and adverse drug reactions. In addition, it offers Phoenix WinNonlin, a platform for non-compartmental analysis, pharmacokinetic/pharmacodynamic, and toxicokinetic; phoenix hosted, that provides a secured and validated certara amazon web services workspace; Phoenix NLME, a population modeling and simulation software for nonlinear mixed effects models; and pirana modeling workbench. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange, used to define data standards and specifications; and Metadata Repository, to enable study design using controlled and standardized data. It serves life sciences companies, biopharmaceutical companies, research organizations, academic institutions, and global regulators, as well as animal health, crop science, bio science, medical devices, and public sector industries. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.

Corporate Governance

Certara, Inc.’s ISS Governance QualityScore as of April 1, 2024 is 6. The pillar scores are Audit: 7; Board: 5; Shareholder Rights: 8; Compensation: 4.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.